A phase IV trial to Assess the Effectiveness of Apixaban compared with usual care anticoagulation in the subjects with Non-Valvular Atrial Fibrillation Undergoing Cardioversion
A study for subjects with Non-Valvular Atrial Fibrillation using study drug Apixaban
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAO1708
U.S. Govt. ID: NCT02100228
Contact: Jose Dizon: 914-428-3888 / jmd11@columbia.edu
Additional Study Information: The purpose of this study is to compare the effectiveness and safety of a study drug called apixaban on patients with non-valvular atrial fibrillation during and after treatment to put them back into a normal heart rhythm (also known as cardioversion) .
This study is closed
Investigator
Jose Dizon, MD
Do You Qualify?
Do you contraindications (negative response) to apixaban or usual care for non-vualvular atrial fibrillation? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jose Dizon
jmd11@columbia.edu
914-428-3888
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE